Recent advances in the molecular and cellular biology of chronic myeloid leukaemia: lessons to be learned from the laboratory.
Holyoake
D T
DT
Academic Transfusion Medicine Unit, Department of Medicine, Royal Infirmary, Glasgow, UK. tlh1g@clinmed.gla.ac.uk
D000818:Animals; D017209:Apoptosis / Q000235:genetics; D001549:Benzamides; D002448:Cell Adhesion / Q000235:genetics; D002453:Cell Cycle; D002461:Cell Line, Transformed; D002986:Clinical Trials as Topic; D003599:Cytoskeleton / Q000473:pathology; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D016044:Fusion Proteins, bcr-abl; D016313:Genes, abl; D006133:Growth Substances / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D023421:Models, Animal; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D015398:Signal Transduction / Q000235:genetics*; D013234:Stem Cells; D016615:Telomere
D001549:Benzamides; D004791:Enzyme Inhibitors; D006133:Growth Substances; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases; D016044:Fusion Proteins, bcr-abl